Chief Scientific Officer Farshad is the Chief Scientific Officer of the Company. Dr. Guirakhoo was named in 2014 as no. 22 in the list of The Most Influential People in Vaccines. Dr. Guirakhoo is the co-inventor of the ChimeriVaxTM-technology platform, the world’s first recombinant viral vector platform that was approved for any human vaccine. Dr. Guirakhoo has broad experience in the application of genetics, gene expression technologies and molecular virology for the constructions and productions of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases and cancers. Dr. Guirakhoo is the author of over 100 peer-reviewed publications, including book chapters, and holds dozens of issued patents. Dr. Guirakhoo received his Ph.D. in Virology from the University of Vienna, Austria, holds an M.Sc. in Genetics and a B.Sc. in Biology. He has been awarded the National Research Council Post-Doctorate Award and studied at the CDC, Division of Vector-Borne Infectious Diseases, in Fort Collins, CO.